Stocks and Investing Stocks and Investing
Thu, March 23, 2023

Andrew Fein Reiterated (BIIB) at Strong Buy and Held Target at $325 on, Mar 23rd, 2023


Published on 2024-10-28 02:23:37 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $325 on, Mar 23rd, 2023.

Andrew has made no other calls on BIIB in the last 4 months.



There are 9 other peers that have a rating on BIIB. Out of the 9 peers that are also analyzing BIIB, 3 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Steve Chesney of "Atlantic Equities" Maintained at Hold with Increased Target to $295 on, Thursday, December 1st, 2022
  • Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $247 on, Wednesday, November 30th, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Increased Target to $313 on, Wednesday, November 30th, 2022


These are the ratings of the 6 analyists that currently disagree with Andrew


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $333 on, Thursday, February 16th, 2023
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $340 on, Thursday, February 16th, 2023
  • Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $310 on, Thursday, February 16th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $351 on, Thursday, February 16th, 2023
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Increased Target to $315 on, Thursday, February 16th, 2023
  • Michael Yee of "Jefferies" Maintained at Strong Buy with Increased Target to $350 on, Wednesday, November 30th, 2022
Contributing Sources